Accelerated Infliximab Infusions Research Articles

Safety of Accelerated Infliximab Infusions in Children With Inflammatory Bowel Disease: A Retrospective Cohort Study.

Accelerated infliximab (IFX) infusions have shown to be safe in adults with inflammatory bowel disease (IBD), but data on its safety in pediatric IBD is limited. This study aimed to assess the incidence and timing of infusion reactions (IR) in children with IBD who received accelerated (1-h) versus standard (2-h) IFX infusions. This retrospective cohort study included IBD patients 4-18 years of age and initiated IFX between January 2006 and November 2021 at Amsterdam University Medical Centre, location Academic Medical Centre (AMC) and VU Medical Centre (VUmc). The AMC protocol was adjusted in July 2019 from standard to accelerated infusions with 1-h intrahospital post-infusion observation period, whereas in VUmc only standard infusions were administered without an observation period. After merging the departments in 2022, all VUmc patients were allocated to the accelerated infusions (AMC) protocol. Primary outcome was the incidence of acute IR among maintenance accelerated versus standard infusions. Totally, 297 (150 VUmc, 147 AMC) patients (221 Crohn disease; 65 ulcerative colitis; 11 IBD-unclassified) with cumulative n = 8381 IFX infusions were included. No statistically significant difference in the per-infusion incidence of IR was observed between maintenance standard infusions (26/4383, 0.6% of infusions) and accelerated infusions (9/3117, 0.3%) ( P = 0.33). Twenty-six of 35 IR (74%) occurred during the infusion, while 9 occurred post-infusion (26%). Only 3 of 9 IR developed in the intrahospital observation period following the switch to accelerated infusions. All post-infusion IR were mild, requiring no intervention or only oral medication. Accelerated IFX infusion without a post-infusion observation period for children with IBD seems a safe approach.

Accelerated Infliximab Infusion Safety and Tolerability Is Non-inferior to Standard Infusion Protocol in Inflammatory Bowel Disease Patients: A Randomized Controlled Study.

Infliximab is typically given over an infusion time of 2 hours, leading to a significant burden in inflammatory bowel disease (IBD) patients. We aimed to determine the safety and cost-effectiveness of an accelerated infliximab infusion of 1 hour, compared with the standard 2-hour infusion. Open-label randomized trial where IBD patients receiving maintenance infliximab infusions were randomly assigned to 1- and 2-hour infusion groups, corresponding to study and control groups, respectively. The primary outcome was the rate of infusion reactions. Secondary outcomes were assessment of the effect of premedications and immunomodulators on the rate of infusion reactions, and cost-effectiveness analysis. The cost-effectiveness analysis was based on direct nursing costs for the infusion time, indirect infusion center costs, and cost of productivity loss for patients. This trial is registered with ClinicalTrials.gov, NCT05340764. From November 2020 to November 2021, 96 patients were randomly assigned: 51 (53%) to the 1-hour infusion group and 45 (47%) to the 2-hour infusion group. Over a median time of 1 year, 309 infusions were administered in the control group, and 376 in the study group. Fifty-seven (18%) infusions in the control group and 45 (12%) infusions in the study group experienced an infusion reaction. The only infusion reaction was asymptomatic hypotension not requiring infusion discontinuation. No other infusion reactions (mild or moderate/severe) were seen. Diphenhydramine was associated with an increased rate of infusion reactions (OR 2.04 [95% CI 1.18-3.52], P = .01). The average costs were estimated to reduce by 37% in the accelerated infusion group. Accelerated 1-hour infusions are non-inferior in safety and superior in cost-effectiveness compared with standard 2-hour infusions in IBD patients receiving maintenance infliximab infusions. Registered with ClinicalTrials.gov, NCT05340764.

ACCELERATED INFLIXIMAB INFUSION SAFETY AND TOLERABILITY IS NON-INFERIOR TO STANDARD INFUSION PROTOCOL IN INFLAMMATORY BOWEL DISEASE PATIENTS – A RANDOMIZED CONTROLLED STUDY

Infliximab is typically given over a standard infusion time of 2 hours, leading to a significant burden in inflammatory bowel disease (IBD) patients. Several retrospective and prospective studies have assessed the safety of accelerated infliximab infusions, but not in a randomized controlled setting. We aimed to determine the safety and cost-effectiveness of an accelerated infliximab infusion of 1 hour, compared to the standard 2 hour infusion.

ACCELERATED INFLIXIMAB INFUSION SAFETY AND TOLERABILITY IS NON-INFERIOR TO STANDARD INFUSION PROTOCOL IN INFLAMMATORY BOWEL DISEASE PATIENTS – A RANDOMIZED CONTROLLED STUDY

Abstract BACKGROUND & AIM Infliximab is typically given over a standard infusion time of 2 hours, leading to a significant burden in inflammatory bowel disease (IBD) patients. Several retrospective and prospective studies have assessed the safety of accelerated infliximab infusions, but not in a randomized controlled setting. We aimed to determine the safety and cost-effectiveness of an accelerated infliximab infusion of 1 hour, compared to the standard 2 hour infusion. METHODS This open label randomized trial was done at a tertiary IBD center in the United States. Patients with an established diagnosis of IBD receiving maintenance infliximab infusions at one of our centers were eligible for inclusion. We excluded patients with a history of infusion reactions and those with known antidrug antibodies to infliximab. Patients were randomly assigned (1:1) to the 1 hour infusion (study) and 2 hour infusion (control) groups using an independent computerized randomization system. The primary outcome was to assess the rate of infusion reactions in the standard 2 hour compared to the accelerated 1 hour study groups. Secondary outcomes were assessment of the effect of pre-medications and concomitant immunomodulators on the rate of infusion reactions, and cost effectiveness analysis. Sample size calculation was based on an infusion reaction rate of 3%, as suggested by recent studies. In order to show a non-inferiority of the accelerated infusion time assuming an infusion reaction rate of 3% while allowing for a 4% non-inferiority limit, a total of 538 infusions would be needed. This would provide a power of 80% and significant alpha of 0.05. Non-inferiority was assessed using Farrington-Manning score test. This trial is registered with ClinicalTrials.gov, NCT05340764. RESULTS From November 2020 to November 2021, we assessed the eligibility of 448 patients, of whom 352 (78%) were excluded primarily due to infusions being received at an outside institution, or patient refusal. Thus, 96 (22%) patients were randomly assigned: 51 (53%) to the 1 hour infusion study group and 45 (47%) to the 2 hour infusion control group. Over a median time of 1 year, a total of 685 infusions were administered: 309 infusions in the control group, and 376 in the study group. 57 (18%) of 309 infusions in the control group and 45 (12%) of 376 infusions in the study group experienced an infusion reaction. The only infusion reaction experienced was hypotension, all of which were asymptomatic and none required infusion discontinuation. Diphenhydramine was associated with an increased rate of infusion reactions (OR 2.04 [95% CI 1.18 – 3.52], p=0.01). Average costs were estimated to reduce by 37% in the accelerated infusion group. CONCLUSION Accelerated 1 hour infliximab infusions are non-inferior in safety and superior in cost-effectiveness compared to standard 2 hour infusions in IBD patients.

Safety, satisfaction and cost savings of accelerated infusions of standard and intensified-dose infliximab for inflammatory bowel disease.

Infliximab remains a mainstay for the treatment of inflammatory bowel disease (IBD), but a long infusion duration and subsequent monitoring can be burdensome to patients and healthcare providers. To assess the safety of accelerated infusions for standard and dose-intensified infliximab regimens, and the effect on patient satisfaction and potential cost savings. Patients with IBD on a stable maintenance dose of infliximab and in clinical remission received one or more accelerated infusions: over 30 min if receiving a standard dose (5 mg/kg), or over 60 min if receiving dose-intensified infliximab (up to 10 mg/kg). Outcomes included incidence of reactions (acute or delayed), patient satisfaction and potential cost savings. We also explored infliximab trough levels after one and three accelerated infusions. Fifty-two patients who received 150 infusions were studied. Incidence of reactions to accelerated infusions was 3.3% (3 out of 89) with a standard dose and 0% (out of 61) with dose-intensified infliximab. Reactions were delayed, mild and self-limiting. None required drug cessation. Patient satisfaction was improved with shortened infusion time as compared with the patients' previous experiences (P = 0.00002). Mean plasma trough level of infliximab reduced from 9.3 mg/L (±4.9) to 7.9 mg/L (±4.1) (P = 0.02) with accelerated infusions, but none developed anti-infliximab antibodies. Nursing cost savings were estimated as $123.52 and $247.04 per patient per year for standard and dose-intensified infliximab respectively. Accelerated infliximab infusions for standard and dose-intensified regimens seem to be safe and improved patient satisfaction. Potential impact on drug trough levels requires further investigations.

A quality improvement project reduces time spent at an inflammatory bowel disease infusion center with accelerated infliximab infusion protocol.

Background and AimPatients with inflammatory bowel disease (IBD) requiring infliximab frequently spend hours to attend treatment. Through quality improvement (QI) methodology, we aimed to shorten the time spent in the biologics infusion center using the accelerated infusion protocol and describe patient outcomes, safety, and associated cost savings.MethodsFrom September 2018 through December 2019, eligible IBD patients receiving infliximab were recruited. We implemented interventions including the accelerated infusion protocol, and modifying collection location of infliximab. Statistical process control charts were created. Patients' clinical outcome and cost savings data were analyzed using descriptive statistics and Pearson's chi‐square.ResultsDuring the study period, a total of 60 patients with IBD receiving infliximab were recruited. A total of 315 infusions were administered—152 were under accelerated infusion protocol and 163 under standard protocol. The mean infliximab infusion time was reduced by 47%, from 2.4 h (142 ± 14 min) to 1.2 h (75 ± 10 min) (142 min vs 75 min, P < 0.001), with total time spent in the infusion center reduced by 52%, from 3.6 h (214 ± 25 min) to 1.7 h (102 ± 14 min) (214 vs 106 min, P < 0.001). Three mild infusion‐related reactions (3/152 = 1.97%) were recorded. Estimated cost savings over the 16‐month project period was SGD $6721.4 (nursing) and SGD $23 560 (patients). A high level of satisfaction (4.84 out of 5) with the protocol was reported.ConclusionOur QI project shortened the infliximab infusion time and total time spent in the infusion center, without compromising patient safety. Estimated cost savings were substantial. The protocol helps reduce work productivity loss.

776 Accelerated Infliximab Infusion Protocol for Inflammatory Bowel Disease: A Safety and Cost-Effectiveness Study in an Asian Tertiary Center

INTRODUCTION: The recommended infusion time for infliximab for inflammatory bowel disease (IBD) is 2 hours or more. Time spent on receiving infliximab infusions in the hospital disrupts school and work activities. Significant nursing time is also spent which increases healthcare costs. Shortening infliximab infusion to over 1 hour has been shown to be safe and has the potential to decrease time spent in hospital. This study aims to determine the safety and effectiveness of this accelerated infliximab infusion protocol in patients with IBD in Southeast Asia. METHODS: We conducted a retrospective study on patients with Crohn's disease (CD) and ulcerative colitis (UC), who received infliximab from September 2018 to May 2019 at Singapore General Hospital. Patients on stable maintenance infliximab were offered the accelerated protocol if they had tolerated ≥4 infliximab infusions without reactions. The need for pre-medications was determined by the prescribing physician. Primary endpoint was infusion-related reaction rate and secondary endpoints were cost and time saved per infusion. RESULTS: A total of 187 infusions were administered to 57 patients (53 CD, 4 UC). The mean age was 52.0 ± 17.0 years and 61.4% of the subjects were male. Out of the 57 patients, 22 of them received the accelerated infusion protocol with a total of 86 1-h infusions. Three reactions (1 immediate, 2 delayed) were observed during the 1-h infusions and were reverted back to the standard 2-h infusion subsequently. However, this was not found to be statistically significant after adjustment for age, sex, administration of pre-medications or types of disease. The median time spent per infusion in the hospital for the accelerated infusion protocol was significantly reduced compared to for the standard infusion (138 ± 26 minutes vs. 216 ± 26 minutes; P &lt; 0.05). This improvement amounts to an estimate of 65 minutes returned to the patient for normal activities outside of the hospital per infusion. There was also a reduction in nursing time and cost (S$ 42.9 per infusion and 46.4% relative cost reduction) to the hospital. CONCLUSION: The accelerated infliximab infusion protocol is safe in our cohort of IBD patients. It also results in a decrease in in-hospital time for patients and improves the efficiency of healthcare delivery.

Safety and Tolerability of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease.

Infliximab for inflammatory bowel disease (IBD) is FDA-approved to be administered 2 h or more. We adopted a new protocol to infuse infliximab over 1 h and in this study, we aimed to determine the safety of a 1-h infusion. This retrospective cohort included adult IBD patients who received infliximab between June and December 2017 and compared reaction rates of 1-h maintenance infusions to that of 2-h maintenance infusions. A total of 551 infusions were administered to 179 patients. The infusion groups demonstrated no significant differences in reaction rates. Infliximab infusion over 1 h is well-tolerated.

Evaluation of the safety and satisfaction of rheumatic patients with accelerated infliximab infusion

IntroductionInfliximab infusion generally occurs in 2–4 h. Recent studies have suggested the possibility of accelerated infusion (1 h) of this drug.ObjectiveTo evaluate the safety of accelerated infliximab infusion in patients with rheumatic diseases. In addition, patient satisfaction was also assessed.MethodsA prospective, single-center, non-randomized study with 34 patients with rheumatic diseases was conducted from July to November 2016. Patients with the following were excluded: history of allergic reaction to biologics, asthma or severe atopy. All patients previously received a 2- to 3-h infliximab infusion. The infusion rate was accelerated to 1 h, and premedication was excluded. The infusion was monitored in all patients.ResultsA total of 34 patients were included in the study [rheumatoid arthritis (n = 16), ankylosing spondylitis (n = 15), psoriatic arthritis (n = 2) and enteropathic arthropathy (n = 1)], with an average age of 48.7 ± 18.6 years; 55.5% of the patients were female, and 29.4% were white. The duration of disease was 9.5 ± 9.2 years, and the duration of infliximab use was 38.9 ± 27.6 months, with a mean dose per infusion of 414.2 ± 158.1 (range, 200–800) mg. The mean infliximab infusion time prior to the study was 2.2 ± 0.4 h. A total of 6 (17.6%) patients received premedication. The premedication was suspended. There were no adverse effects during or after infusion. Ninety-seven percent of the patients and 100% of the health workers were satisfied with the accelerated infusion.ConclusionOur data support the safe use of accelerated infliximab infusion in rheumatic patients, with high satisfaction among patients and health workers.

Accelerated Infliximab Infusion: Safety, Factors Predicting Adverse Events, Patients' Satisfaction and Cost Analysis. A Cohort Study in IBD Patients.

BackgroundStandard Infliximab infusion consists of a 2-hour intravenous administration. Recently, Infliximab shortened infusion has been included in the Infliximab label as possible maintenance regimen for patients tolerating Infliximab induction therapy.AimTo verify if accelerated 1-hour Infliximab infusions are as safe as standard administrations, in patients with Inflammatory Bowel Disease.MethodsSeventy-four patients treated between September 2008 and November 2014 were evaluated. Patients were eligible for 1-hour infusion if they had no history of infusion reactions during the previous 2-hour infusions.ResultsTwenty-three patients received 2-hour infusions, 16 patients received 1-hour infusions, 35 patients received 2-hour infusions followed by 1-hour infusions. A total of 1,123 Infliximab infusions were administered. The proportion of patients experiencing infusion reaction was: 4% over the 1-hour infusions and 9% over the 2-hour (P = 0.318). Adverse reaction/infusion rate was 0.55% over the 1-hour infusions and 0.66% over the 2-hour (P = 0.835). In the logistic model, accelerated infusion was the only statistically significant predictor of infusion reaction risk reduction (-90%; P = 0.024). Mean satisfaction was 8/10 (±0.84) with 1-hour regimen and 6/10 (±0.56) with 2-hour infusions (P = 0.000). The mean total cost was reduced by 47% with the 1-hour regimen (133.54€ and 250.86€ for 1-hour and 2-hour infusions, respectively).ConclusionsAccelerated Infliximab infusion does not increase the acute infusion reaction incidence. In patients with inflammatory bowel disease, the 1-hour regimen should be preferred to 2-hour protocol also due to positive effects on indirect costs and patient’s satisfaction.

Sa1206 Long-Term Safety and Efficacy of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease

Sa1206 Long-Term Safety and Efficacy of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease

Sa1207 Endoscopic Examination Is Necessary for Deciding to Discontinue Infliximab in Patients With Refractory Ulcerative Colitis Who Have Maintained Clinical Remission With Infliximab Maintenance Treatment

Background: Infliximab is typically administered to patients with inflammatory bowel disease (IBD) using a 2-hour infusion interval. Several studies have shown that shortened infusion intervals are well tolerated and are associated with increased patient satisfaction. The aim of this study was to determine long-term safety and efficacy of accelerated infliximab infusions in a cohort of IBD patients. Methods: A cohort of IBD patients on stable maintenance dosing of infliximab were offered accelerated infusions at our institution. Patients initially received infusions over a 90 minute interval, and if tolerated then continued with 60 minute infusions at each subsequent infusion. Patient demographics, number of accelerated infusions, and acute or delayed infusion reactions were recorded. Results: 44 patients with IBD (24 male, 8 ulcerative colitis) on stable infliximab dosing received accelerated infusions at our institution. A total of 652 accelerated infusions were administered. Median duration of accelerated infusions was 27 months (range 8-35 months). Mild acute infusion reactions were reported in 0.8% (5/652) and did not recur with return to 2 hour infusions. No severe infusion reactions were reported. No patients discontinued infliximab due to loss of response, although adjustments in infliximab dose or frequency occurred in 10 patients during the follow up period. Patient satisfaction with accelerated infusions was high (90%). Conclusion: Accelerated (60 minute) infliximab infusions were safe and well tolerated in our cohort of IBD patients. Accelerated infusions were associated with an acceptably low risk of infusion reaction and were not associated with a significant risk of loss of response over a median of 27 months of follow up. Patient acceptance of accelerated infliximab infusions was high and is consistent with results from prior studies.

PTU-094 Do We Need Post Infliximab Infusion Monitoring?

IntroductionInfliximab is used in the treatment of inflammatory bowel disease. It is administered as an intravenous infusion over 2 h with a 2 h monitoring period. Accelerated infusions have been...

Letter: the feasibility and safety of accelerated infliximab infusions in patients with inflammatory bowel disease

Letter: the feasibility and safety of accelerated infliximab infusions in patients with inflammatory bowel disease

Safety and cost benefit of an accelerated infliximab infusion protocol in the treatment of ambulatory patients with inflammatory bowel diseases

Background: Infliximab is recommended to be infused over 2 h, but accelerated infusion rates of 30 min may improve efficiency, patient satisfaction and reduce nursing time and cost. The safety of this approach is not established. This study aims to assess the safety of accelerated infliximab infusion and determine the direct cost savings.Methods: The primary endpoint of the study was adverse events and the secondary endpoints were cost, time saving per infusion and patient satisfaction associated with an accelerated infusion protocol.Results: One hundred and thirty-six and 342 infusions were administered to 23 and 39 patients in the standard and accelerated protocols, respectively (mean infusion times 150 and 73.4 min, respectively, p < 0.0001). The adverse reaction rate of the standard protocol was 2.2% (95% confidence interval: 0.46 – 6.57) and accelerated protocol was 3.2% (95% CI: 1.74 – 5.73; p = 0.77). The odds ratio of adverse reaction for the 30-min infusion was 0.40 (95% CI: 0.09 – 1.82). The relative direct cost of nursing was decreased by 51.1% per infusion. Patient satisfaction score of the accelerated protocol was 9.2/10 (95% CI: 8.55 – 9.76) compared to 8.5/10 (95% CI: 7.83 – 9.17) in the initiation phase (p = 0.018).Conclusions:Accelerated 30-min infliximab infusions significantly reduced nursing time, cost and increased patient satisfaction without increasing infusion reactions. Increased patient freedom and improved efficiency in healthcare delivery can be expected.

A nurse-led accelerated infliximab infusion service: patient satisfaction and safety

Many inflammatory bowel disease (IBD) nurse specialists now have the responsibility of managing a biologics service, and with more referrals come issues of bed capacity and patient satisfaction. While accelerated infusions—where infliximab is given according to a structured protocol over a shorter period—have been shown to be safe in rheumatology patients, there are limited data looking specifically at IBD patients. In this paper, Kay Greveson and Sue Woodward describe a prospective service development review that was conducted to determine the incidence of infusion-related reactions with an accelerated-infusion protocol and to explore patient perceptions of a nurse-led accelerated-infusion regimen.

Tu1244 Are Accelerated Infliximab Infusions Safe to Administer in Patients With Inflammatory Bowel Disease?

Tu1244 Are Accelerated Infliximab Infusions Safe to Administer in Patients With Inflammatory Bowel Disease?

Accelerated infliximab infusions for inflammatory bowel disease improve effectiveness

To study the safety and effectiveness associated with accelerated infliximab infusion protocols in patients with inflammatory bowel disease (IBD). Original protocols and infusion rates were developed for the administration of infliximab over 90-min and 60-min. Then the IBD patients on stable maintenance infliximab therapy were offered accelerated infusions. To be eligible for the study, patients needed a minimum of four prior infusions. An initial infusion of 90-min was given to each patient; those tolerating the accelerated infusion were transitioned to a 60-min infusion protocol at their next and all subsequent visits. Any patient having significant infusion reactions would be reverted to the standard 120-min protocol. A change in a patient's dose mandated a single 120-min infusion before accelerated infusions could be administered again. The University of Virginia Medical Center's Institutional Review Board approved this study. Fifty IBD patients treated with infliximab 5 mg/kg, 7.5 mg/kg and 10 mg/kg were offered accelerated infusions. Forty-six patients consented to participate in the study. Nineteen (41.3%) were female, five (10.9%) were African American and nine (19.6%) had ulcerative colitis. The mean age was 42.6 years old. Patients under age 18 were excluded. Ten patients used immunosuppressive drugs concurrently out of which six were taking azathioprine, three were taking 6-mercaptopurine and one was taking methotrexate. One of the 46 study patients used corticosteroid therapy for his IBD. Seventeen of the patients used prophylactic medications prior to receiving infusions; six patients received corticosteroids as pre-medication. Four patients had a history of distant transfusion reactions to infliximab. These reactions included shortness of breath, chest tightness, flushing, pruritus and urticaria. These patients all took prophylactic medications before receiving infusions. 46 patients (27 males and 19 females) received a total of fifty 90-min infusions and ninety-three 60-min infusions. No infusion reactions were reported. There were no adverse events, including drug-related infections. None of the patients developed cancer of any type during the study timeframe. Total cost savings for administration of the both 90-min and 60-min accelerated infusions compared to standard 120-min infusions was estimated to be $53 632 ($116 965 vs $63 333, P = 0.001). One hundred and eighteen hours were saved in the administration of the accelerated infusions (17 160 min vs 10 080 min, P = 0.001). In the study population, overweight females [body mass index (BMI) > 25.00 kg/m(2)] were found to have statistically higher BMIs than overweight males (mean BMI 35.07 ± 2.66 kg/m(2) vs 30.08 ± 0.99 kg/m(2), P = 0.05), finding which is of significance since obesity was described as being one of the risk factors for Crohn's disease. We are the first US group to report substantial cost savings, increased safety and patient satisfaction associated with accelerated infliximab infusion.

Are accelerated infliximab infusions safe in patients with inflammatory bowel disease?

Infliximab is a monoclonal antibody used in the treatment of inflammatory bowel disease (IBD). The manufacturer-recommended administration is over 2 hours followed by 2 hours of patient observation. The data relating to adverse outcomes in patients receiving accelerated infusions for IBD are limited. Our unit utilizes an accelerated protocol for infliximab infusion in selected patients with IBD (those with no adverse reaction in their first four standard infusions). Our aim was to assess if the accelerated infusion protocol (infusion over 1 hour or 30 minutes with 1 hour or no monitoring according to protocol) was associated with any increase in adverse outcomes. Data were collected retrospectively on protocol used and adverse outcomes for all infliximab infusions between October 2005 and June 2008. Out of 69 patients, 27 received the accelerated protocol (130 infusions). All patients received a total of 306 infusions on the standard protocol. No adverse reactions were reported in the accelerated protocol patients. In patients on the standard protocol, 16 adverse reactions were observed: seven were acute (occurring during infusion); nine were delayed (occurring within 1-7 days following infusion). No patient required intramuscular adrenaline or hospitalization. Our findings suggest that an accelerated protocol for infliximab infusion is well tolerated in selected patients. The monitoring period following infusion may not be necessary, as all acute reactions occurred within an hour of initiating infusion and did not warrant hospitalization. The accelerated infusion may allow more efficient utilization of hospital resources and reduce patient inconvenience.

P150 - Tolerability and safety of accelerated infliximab infusions: a prospective referral center registry and patient survey

P150 - Tolerability and safety of accelerated infliximab infusions: a prospective referral center registry and patient survey